A trial looking at weekly chemotherapy for ovarian cancer (ICON 8)
Cancer type:
Status:
Phase:
This trial compared chemotherapy every week with chemotherapy every 3 weeks for ovarian cancer, fallopian tube cancer or primary peritoneal cancer. It was supported by Cancer Research UK.
More about this trial
- is better than 3 weekly chemotherapy for women with ovarian cancer
- causes more or fewer side effects than 3 weekly chemotherapy
Summary of results
- 522 women had both carboplatin and paclitaxel once every 3 weeks (group A)
- 523 women had carboplatin once every 3 weeks, and paclitaxel once a week (group B)
- 521 women had both carboplatin and paclitaxel once a week (group C)
- 24.4 months for those in group A (3 weekly chemotherapy)
- 24.9 months for those in group B (3 weekly carboplatin and weekly paclitaxel)
- 25.3 months for those in group C (weekly chemotherapy)
- 8 out of 10 (80%) of those in group A
- just over 8 out of 10 (82%) of those in group B
- just under 8 out of 10 (78%) of those in group C
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr Andrew Clamp
Supported by
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
Medical Research Council (MRC)
NIHR Clinical Research Network: Cancer
Other information
This is Cancer Research UK trial number CRUK/10/030.
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040